Cytel
Pioneering Global Clinical Trial Innovation

Cytel is a multinational clinical research organization and statistical software developer headquartered in Waltham, Massachusetts. The company is renowned for its expertise in optimizing clinical trials through advanced analytics and adaptive trial designs. Founded in 1987 by research scientists at Harvard University and MIT Cyrus Mehta and Nitin Patel, it has grown into a global leader, supporting drug development for 37 of the world’s 40 largest pharmaceutical companies and regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

With over 1,900 employees across 15 North American, European, and Asian offices, Cytel operates at the intersection of statistical innovation and operational execution, contributing to more than 300 adaptive trials annually. From its early days as a provider of DOS-based statistical tools to its current role as a developer of AI-enhanced clinical trial platforms, the company has remained committed to advancing clinical research methodologies.

“As the world’s leading data-science CRO and pioneers in adaptive trial design, we leverage the power of data to inform your strategy at every stage of drug development,” says Yannis Jemiai, Chief Scientific Officer of Cytel.

At the core of Cytel’s offerings is its ability to solve complex challenges in clinical trial design and execution. As a pioneer in adaptive trial methodologies, the company has developed flexible frameworks like group sequential designs and Bayesian approaches, gaining widespread acceptance among major regulatory bodies. These methodologies allow trial sponsors to modify study parameters based on interim data, reducing costs and accelerating timelines while maintaining statistical rigour.

The biostatistics and programming division provides end-to-end support, from protocol development to regulatory submissions, with specialized expertise in rare diseases, oncology, and cardiovascular research. Further expanding its capabilities, Cytel strengthened its real-world evidence solutions in 2024 by partnering with OneMedNet. This collaboration integrates medical imaging data with electronic health records to enhance observational studies in oncology and cardiology. This collaboration exemplifies the company’s strategy to bridge traditional clinical trial data with real world insights for more robust evidence generation.

Cytel’s software portfolio is another key pillar of its value proposition. The launch of East Horizon in 2024 marked a paradigm shift in trial design, offering a cloud-based platform that enables simulation-guided development. By integrating the legacy capabilities of its established East software with R language support and collaborative workflow features, East Horizon provides a modernized approach to statistical planning.

As the world’s leading data science CRO and pioneers in adaptive trial design, we leverage the power of data to inform your strategy at every stage of drug development

For precise statistical analysis, Cytel offers tools like StatXact and LogXact, which provide exact methods for small-sample studies, making them particularly valuable in early-phase trials and rare disease research. These solutions integrate seamlessly with SAS and other clinical trial management systems. On the operational front, Enforesys leverages historical site performance data to predict recruitment rates, while ACES, introduced in 2024, ensures secure communications for data monitoring committees. Additionally, the OKGO framework, launched in 2023, applies quantitative modelling to assist sponsors in making data-driven go/no-go decisions, reducing subjective bias in portfolio management.

Based on this strong foundation of statistical and operational innovations, Cytel has also demonstrated steady business growth. Since 2024, the company has been backed by Nordic Capital’s Fund X, following its 2021 acquisition by private equity firm Astorg. This strategic investment has fueled Cytel’s expansion, contributing to its reported $328.9 million in revenue in 2024. The increasing demand for complex trial designs and the globalization of clinical research operations have been key drivers of this growth, solidifying Cytel’s position as a trusted partner for 30 top biopharmaceutical companies, particularly in oncology, rare diseases, and central nervous system disorders.

Geographically, Cytel maintains innovation hubs in Cambridge (Massachusetts), Geneva, and Hyderabad, with regional offices in Shanghai, Singapore, and Pune to support the Asia-Pacific market. European operations span Paris, London, and Rotterdam, while North American centres in Seattle, Toronto, and Vancouver focus on adaptive design implementation and data management.

Recent strategic initiatives highlight Cytel’s responsiveness to industry trends. The 2024 validation of its commitments under the Science-Based Targets initiative demonstrates a strong focus on sustainability, with plans to reduce greenhouse gas emissions across its operations and supply chains. In parallel, the company has prioritized digital transformation, incorporating machine learning into its Compass platform to enhance predictive trial analytics and risk-based monitoring. Additionally, through its Cytel Statistical Innovation Institute, the company fosters knowledge-sharing by offering courses in Bayesian methods and real-world evidence to over 5,000 professionals annually.

Looking ahead, Cytel aims to tackle emerging challenges in decentralized trials and personalized medicine, continuing its legacy of combining statistical excellence with technological innovation to reshape global drug development.